{Reference Type}: Journal Article
{Title}: Oncology's trial and error: Analysis of the FDA withdrawn accelerated approvals.
{Author}: Preziosi AJ;Priefer R;
{Journal}: Life Sci
{Volume}: 346
{Issue}: 0
{Year}: 2024 Jun 1
{Factor}: 6.78
{DOI}: 10.1016/j.lfs.2024.122615
{Abstract}: Launched in 1992, the FDA accelerated approval program grants drugs indicated in rare/life threatening diseases the ability to be marketed at a faster pace than through the traditional track. Each manufacturing company presents its drug to the FDA, and within 60 days it will determine if the drug is eligible for this path. Many drugs that were initially approved through this route, subsequently did not demonstrate their clinical benefits. With cancer being a leading cause of death, a vast majority of drugs that have been approved/withdrawn from this pathway are indicated within oncology. There are a wide variety of cancer subtypes and therapeutic target sites that these drugs have been evaluated for. Herein, is an overview of the 17 oncology drugs, spanning 22 cancer-related indications, that had been approved within the accelerated route and subsequently withdrawn.